Pliant Therapeutics, Inc. Files Definitive Proxy Statement

TL;DR

<b>Pliant Therapeutics, Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023, detailing executive compensation and equity award information.</b>

AI Summary

PLIANT THERAPEUTICS, INC. (PLRX) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Pliant Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 22, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 260 Littlefield Avenue, South San Francisco, CA 94080. The filing includes information related to equity awards granted and outstanding for the fiscal years 2021, 2022, and 2023. Details on the fair value of equity awards, changes in fair value, and vesting conditions are presented for both PEO and Non-PEO members.

Why It Matters

For investors and stakeholders tracking PLIANT THERAPEUTICS, INC., this filing contains several important signals. This filing provides crucial details on executive compensation and equity awards, which are key components of shareholder value and executive incentives. Understanding the details of equity awards, their valuation, and vesting schedules is important for investors to assess management's alignment with shareholder interests and the company's long-term strategy.

Risk Assessment

Risk Level: low — PLIANT THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

Analyst Insight

Review the executive compensation details and equity award structures to understand management incentives and potential dilution.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-04-22 — Filing Date (Date of filing)

Key Players & Entities

• PLIANT THERAPEUTICS, INC. (company) — Filer name
• 2024-04-22 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end
• 260 Littlefield Avenue (address) — Business address
• SOUTH SAN FRANCISCO (location) — Business address city
• CA (location) — Business address state
• 94080 (postal_code) — Business address zip
• 650-481-6770 (phone_number) — Business phone

FAQ

Industry Context

Pliant Therapeutics operates in the pharmaceutical preparations industry, focusing on developing treatments for fibrotic and related diseases.

Regulatory Implications

As a publicly traded company, Pliant Therapeutics is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings and disclosures.

What Investors Should Do

1. Analyze the compensation structure for named executive officers.
2. Evaluate the details of equity awards, including grants, vesting, and fair value.
3. Review any proposals presented to shareholders for voting.

Key Dates

• 2024-04-22: DEF 14A Filing — Definitive Proxy Statement filed, providing details on corporate governance and executive compensation.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document. No prior filing details are available in this extract for comparison.

Key Financial Figures

• $0.0001 — 2 shares of our common stock, par value $0.0001 per share, outstanding on the record da

Filing Documents

• plrx-20240422.htm (DEF 14A) — 844KB
• plrx-20240422_g1.jpg (GRAPHIC) — 44KB
• plrx-20240422_g2.jpg (GRAPHIC) — 12KB
• plrx-20240422_g3.jpg (GRAPHIC) — 66KB
• plrx-20240422_g4.jpg (GRAPHIC) — 67KB
• plrx-20240422_g5.jpg (GRAPHIC) — 419KB
• plrx-20240422_g6.jpg (GRAPHIC) — 196KB
• plrx-20240422_g7.jpg (GRAPHIC) — 119KB
• plrx-20240422_g8.jpg (GRAPHIC) — 117KB
• 0001746473-24-000057.txt (&nbsp;) — 3885KB
• plrx-20240422.xsd (EX-101.SCH) — 1KB
• plrx-20240422_htm.xml (XML) — 145KB

Executive Compensation

Executive Compensation 21 Pay Versus Performance 3 4 Certain Relationships and Related Party Transactions 37 Principal Stockholders 38 Proposal No. 3 - Ratification of the Appointment Of Deloitte & Touche LLP as Pliant's Independent Registered Public Accounting Firm for the Year Ending December 31, 2024 41 Report of the Audit Committee 42 Stockholders Proposals 42 Other Matters 43 TABLE OF CONTENTS PLIANT THERAPEUTICS, INC. 260 Littlefield Avenue South San Francisco, CA 94080 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 13, 2024 This proxy statement contains information about the 2024 Annual Meeting of Stockholders, (the "Annual Meeting") of Pliant Therapeutics, Inc., (the "Company"), which will be held on Thursday, June 13, 2024 at 8:30 a.m. Pacific Time. The 2024 Annual Meeting will be a virtual stockholders meeting held on the Internet at www.virtualshareholdermeeting.com/PLRX2024. The board of directors of the Company (the "Board") is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms "Pliant," "Company," "we," "us," and "our" refer to Pliant Therapeutics, Inc. The mailing address of our principal executive offices is 260 Littlefield Avenue, South San Francisco, CA 94080. Information made available on our website is not incorporated by reference into this proxy statement. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our Board with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at the meeting by (1) following the instructions on the Notice and entering a new vote by mail that we receive before the start of the Annual Meeting or over the Internet by the cutoff time of 11:59 p.m. Eastern

View Full Filing

View this DEF 14A filing on SEC EDGAR